Coronary diseaseLesion typeBifurcations

03/03 | SOLACI Webinar – Left Main PCI and Bifurcations: LATAM Bif Registry

solaci
solaci
649
0

We invite you to participate in the first free SOLACI virtual event of 2021. It is carried out with the support of Abbott, Boston Scientific, Medtronic and Terumo Interventional Systems and will have the participation of prestigious hemodynamicists from Latin America and the world.

The title of the event is: “Left Main PCI and Bifurcations: LATAM Bif Registry“.

The event will take place next Wednesday, March 3 at 5:00 p.m. (Argentine time).

The event is open and free and requires prior registration.

Check the program and register!

Register Here
SOLACI Webinar - Left Main PCI and Bifurcations: LATAM Bif Registry

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
Regression of High-Risk Plaque with Lifestyle Changes
Next article
Asymptomatic Patients: The Key to Understand the Prevalence of the COVID-19 Pandemic
solaci
solaci

More articles by this author

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

solaci - 0
Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology Congress, Dr. Dimytri Siqueira...

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Dr. Omar Tupayachi - 0
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Dr. Omar Tupayachi - 0
Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Institutional News

ACC 2026: SURViV Trial Results – Exclusive Presentation and Analysis with Dr. Dimytri Siqueira

Following the presentation of the SURViV trial in the Late Breaking Clinical Trials sessions at the American College of Cardiology...
solaci -
SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Dr. Omar Tupayachi - 0
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Dr. Omar Tupayachi - 0
Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

Dr. Omar Tupayachi - 0
The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...